DE2645307A1 - Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen - Google Patents
Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungenInfo
- Publication number
- DE2645307A1 DE2645307A1 DE19762645307 DE2645307A DE2645307A1 DE 2645307 A1 DE2645307 A1 DE 2645307A1 DE 19762645307 DE19762645307 DE 19762645307 DE 2645307 A DE2645307 A DE 2645307A DE 2645307 A1 DE2645307 A1 DE 2645307A1
- Authority
- DE
- Germany
- Prior art keywords
- berlin
- bank
- account
- estrogen
- berliner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 69
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 34
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 32
- 229960001348 estriol Drugs 0.000 claims description 32
- 239000000262 estrogen Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 229940011871 estrogen Drugs 0.000 claims description 29
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 19
- 235000015244 frankfurter Nutrition 0.000 claims description 13
- 239000000583 progesterone congener Substances 0.000 claims description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 7
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 6
- 229960004400 levonorgestrel Drugs 0.000 claims description 6
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 4
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 4
- 229960000978 cyproterone acetate Drugs 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000012937 correction Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 229960001652 norethindrone acetate Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 31
- 229920002261 Corn starch Polymers 0.000 description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 21
- 239000008120 corn starch Substances 0.000 description 21
- 229940099112 cornstarch Drugs 0.000 description 21
- 239000008101 lactose Substances 0.000 description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 21
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 21
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 21
- 239000000454 talc Substances 0.000 description 20
- 229910052623 talc Inorganic materials 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229960004766 estradiol valerate Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 210000005000 reproductive tract Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- -1 17-hydroxy-progesterone ester Chemical class 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000002159 estradiols Chemical class 0.000 description 2
- 229960003836 estriol succinate Drugs 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 235000021167 banquet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 150000002166 estriols Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000005907 ketalization reaction Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762645307 DE2645307A1 (de) | 1976-10-05 | 1976-10-05 | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
| NL7709742A NL7709742A (nl) | 1976-10-05 | 1977-09-05 | Geneesmiddel voor het behandelen van climacterische verschijnselen, alsmede werkwijze voor het bereiden daarvan. |
| US05/837,323 US4145416A (en) | 1976-06-23 | 1977-09-27 | Novel agents and novel methods for treatment of climacteric disturbances |
| GB40925/77A GB1578240A (en) | 1976-10-05 | 1977-10-03 | Medicament pack and agent for the treatment of climacteric deficiency symptoms |
| DK438077A DK438077A (da) | 1976-10-05 | 1977-10-04 | Midler og metode til behandling af klimateriske mangelsymptomer |
| SE7711102A SE7711102L (sv) | 1976-10-05 | 1977-10-04 | Nya medel och nya sett att behandla klimakteriska bortfallsymptom |
| CA288,196A CA1090256A (en) | 1976-10-05 | 1977-10-05 | Medicament pack and agent for the treatment of climacteric deficiency symptoms |
| AU29364/77A AU512918B2 (en) | 1976-10-05 | 1977-10-05 | Treatment of climacteric deficiency systems |
| ZA00775980A ZA775980B (en) | 1976-10-05 | 1977-10-05 | Medicament pack and agent for the treatment of climacteric deficiency symptoms |
| BE181485A BE859410A (fr) | 1976-10-05 | 1977-10-05 | Nouveaux produits et procedes de traitement de troubles de la menopause |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762645307 DE2645307A1 (de) | 1976-10-05 | 1976-10-05 | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2645307A1 true DE2645307A1 (de) | 1978-04-06 |
| DE2645307C2 DE2645307C2 (enrdf_load_stackoverflow) | 1988-10-13 |
Family
ID=5989934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762645307 Granted DE2645307A1 (de) | 1976-06-23 | 1976-10-05 | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
Country Status (9)
| Country | Link |
|---|---|
| AU (1) | AU512918B2 (enrdf_load_stackoverflow) |
| BE (1) | BE859410A (enrdf_load_stackoverflow) |
| CA (1) | CA1090256A (enrdf_load_stackoverflow) |
| DE (1) | DE2645307A1 (enrdf_load_stackoverflow) |
| DK (1) | DK438077A (enrdf_load_stackoverflow) |
| GB (1) | GB1578240A (enrdf_load_stackoverflow) |
| NL (1) | NL7709742A (enrdf_load_stackoverflow) |
| SE (1) | SE7711102L (enrdf_load_stackoverflow) |
| ZA (1) | ZA775980B (enrdf_load_stackoverflow) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3029726A1 (de) * | 1980-08-06 | 1982-02-25 | Werner Dr.med. 4400 Münster Steinschulte | Postkoitale kontrazeptiva mit norgestrel oder levonorgestrel |
| DE3229612A1 (de) * | 1981-08-10 | 1983-02-24 | Syntex (U.S.A.) Inc., 94304 Palo Alto, Calif. | Pharmazeutische packung |
| DE4019670A1 (de) * | 1990-06-22 | 1992-01-09 | Erhard Dr Med Roemer | Arzneimittel zur behandlung der wechseljahre der frau |
| DE4104385C1 (enrdf_load_stackoverflow) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
| EP0309263B1 (en) * | 1987-09-24 | 1994-03-09 | Jencap Research Limited | Hormone composition and use |
| DE4308406C1 (de) * | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
| DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
| EP0696454A2 (de) | 1994-08-12 | 1996-02-14 | JENAPHARM GmbH | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| USRE36247E (en) * | 1983-08-05 | 1999-07-06 | Woco Investments, Ltd. | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| US8071577B2 (en) | 2004-04-20 | 2011-12-06 | Bayer Pharma Aktiengesellschaft | Multi-phase contraceptive preparation based on a natural estrogen |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| US8349820B2 (en) | 2006-10-20 | 2013-01-08 | Bayer Pharma Aktiengesellschaft | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3864210D1 (de) * | 1987-07-06 | 1991-09-19 | Akzo Nv | Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden. |
| US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3639600A (en) * | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
| US3639599A (en) * | 1967-10-19 | 1972-02-01 | Merck Patent Gmbh | Uterotropic composition |
| DE2529523C2 (de) * | 1975-06-30 | 1987-04-30 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur Behandlung klimakterischer Ausfallerscheinungen |
-
1976
- 1976-10-05 DE DE19762645307 patent/DE2645307A1/de active Granted
-
1977
- 1977-09-05 NL NL7709742A patent/NL7709742A/xx not_active Application Discontinuation
- 1977-10-03 GB GB40925/77A patent/GB1578240A/en not_active Expired
- 1977-10-04 SE SE7711102A patent/SE7711102L/ not_active Application Discontinuation
- 1977-10-04 DK DK438077A patent/DK438077A/da not_active Application Discontinuation
- 1977-10-05 CA CA288,196A patent/CA1090256A/en not_active Expired
- 1977-10-05 AU AU29364/77A patent/AU512918B2/en not_active Expired
- 1977-10-05 BE BE181485A patent/BE859410A/xx not_active IP Right Cessation
- 1977-10-05 ZA ZA00775980A patent/ZA775980B/xx unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3639599A (en) * | 1967-10-19 | 1972-02-01 | Merck Patent Gmbh | Uterotropic composition |
| US3639600A (en) * | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
| DE2529523C2 (de) * | 1975-06-30 | 1987-04-30 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur Behandlung klimakterischer Ausfallerscheinungen |
Non-Patent Citations (1)
| Title |
|---|
| UFER J.: Hormontherapie in der Frauenheilkunde, 5.Aufl., W. de Gruyter, Berlin 1978, S.23-26 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3029726A1 (de) * | 1980-08-06 | 1982-02-25 | Werner Dr.med. 4400 Münster Steinschulte | Postkoitale kontrazeptiva mit norgestrel oder levonorgestrel |
| DE3229612A1 (de) * | 1981-08-10 | 1983-02-24 | Syntex (U.S.A.) Inc., 94304 Palo Alto, Calif. | Pharmazeutische packung |
| USRE36247E (en) * | 1983-08-05 | 1999-07-06 | Woco Investments, Ltd. | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| EP0309263B1 (en) * | 1987-09-24 | 1994-03-09 | Jencap Research Limited | Hormone composition and use |
| DE4019670A1 (de) * | 1990-06-22 | 1992-01-09 | Erhard Dr Med Roemer | Arzneimittel zur behandlung der wechseljahre der frau |
| DE4104385C1 (enrdf_load_stackoverflow) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
| DE4308406C1 (de) * | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
| DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
| EP0696454A2 (de) | 1994-08-12 | 1996-02-14 | JENAPHARM GmbH | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| US5633242A (en) * | 1994-08-12 | 1997-05-27 | Oettel; Michael | Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component |
| US8071577B2 (en) | 2004-04-20 | 2011-12-06 | Bayer Pharma Aktiengesellschaft | Multi-phase contraceptive preparation based on a natural estrogen |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| US8349820B2 (en) | 2006-10-20 | 2013-01-08 | Bayer Pharma Aktiengesellschaft | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido |
Also Published As
| Publication number | Publication date |
|---|---|
| DK438077A (da) | 1978-04-06 |
| CA1090256A (en) | 1980-11-25 |
| NL7709742A (nl) | 1978-04-07 |
| GB1578240A (en) | 1980-11-05 |
| AU512918B2 (en) | 1980-11-06 |
| SE7711102L (sv) | 1978-04-06 |
| AU2936477A (en) | 1979-04-12 |
| BE859410A (fr) | 1978-04-05 |
| DE2645307C2 (enrdf_load_stackoverflow) | 1988-10-13 |
| ZA775980B (en) | 1978-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69118494T2 (de) | Kontrazeptionsverfahren und Schema | |
| DE2365103A1 (de) | Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten | |
| DE2645307A1 (de) | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen | |
| EP0196268B1 (de) | Estriolester | |
| DE69901250T2 (de) | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität | |
| DE2310963A1 (de) | Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten | |
| DE1617686A1 (de) | Verfahren zur Anregung von Ovulationszyklen und pharmazeutische Verpackungseinheiten | |
| DE3022337A1 (de) | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen | |
| DE2431704A1 (de) | Stufenkombinationspraeparate per kontrazeption | |
| DE2900061A1 (de) | Prostaglandin-derivate | |
| WO2004014935A1 (de) | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie | |
| DE10236405A1 (de) | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie | |
| DE2529523A1 (de) | Neue mittel und neue methoden zur behandlung klimakterischer ausfallserscheinungen | |
| DE3741801A1 (de) | 17-methylen-estratriene | |
| DE2431694A1 (de) | Kontrzeptionsmittel und kontrazeptivumpackung | |
| DE2548413A1 (de) | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion | |
| DE2218831A1 (de) | Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten | |
| DE2059338C3 (de) | Verwendung von Cyproteronacetat bei der Behandlung der Pubertas praecox | |
| DE3741800A1 (de) | 17-halogenmethylen-estratriene | |
| DE1193941B (de) | Verfahren zur Herstellung von therapeutisch wirksamen 16beta-Alkyl-9alpha-fluor-11beta, 17alpha, 21-trioxy-4-pregnen-3, 20-dion-21-acylaten bzw. des entsprechenden 2 | |
| DE2508775C2 (de) | 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung | |
| DE1617818B2 (de) | Oral verabreichbare oder injizierbare antikonzeptionsmittel | |
| DE2330581A1 (de) | Steroidyloestratriene, ihre verwendung und verfahren zur herstellung derselben | |
| DE1902641C3 (de) | 3-Cyclopentyloxysteroide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1493161C3 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8161 | Application of addition to: |
Ref document number: 2529523 Country of ref document: DE Format of ref document f/p: P |
|
| 8176 | Proceedings suspended because of application no: |
Ref document number: 2529523 Country of ref document: DE Format of ref document f/p: P |
|
| AF | Is addition to no. |
Ref country code: DE Ref document number: 2529523 Format of ref document f/p: P |
|
| 8178 | Suspension cancelled | ||
| AF | Is addition to no. |
Ref country code: DE Ref document number: 2529523 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |